Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 11,800 shares, a growth of 16.8% from the August 31st total of 10,100 shares. Based on an average daily trading volume, of 519,700 shares, the days-to-cover ratio is presently 0.0 days.

Scinai Immunotherapeutics Stock Performance

Shares of NASDAQ SCNI traded down $0.50 during trading hours on Friday, hitting $3.64. The company’s stock had a trading volume of 144,750 shares, compared to its average volume of 363,411. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $9.24. The business has a 50-day simple moving average of $3.84 and a 200-day simple moving average of $4.08. The stock has a market cap of $1.69 million, a price-to-earnings ratio of -0.01 and a beta of 2.48.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($3.57) EPS for the quarter. The firm had revenue of $0.28 million during the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.